ACS CLINICAL RESEARCH PROGRAM
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin, 2014; 64( 1):9-
2. Shah MA. Gastrointestinal cancer: Targeted therapies in gastric cancer—the dawn
of a new era. Nat Rev Clin Oncol. 2014; 11( 1): 10-11.
3. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer—slow but steady
progress. Cancer Treat Rev. 2010; 36( 5):384-392.
4. Shah MA, Kelsen DP. Gastric cancer: A primer on the epidemiology and biology of
the disease and an overview of the medical management of advanced disease. J Natl
Compr Canc Netw. 2010; 8( 4):437-447.
5. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. New Engl J Med. 2006;355( 1):11-
6. Ychou M, Boige V, Pignon J, et al. Perioperative chemotherapy compared with
surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and
FFCD Multicenter phase III trial. J Clin Oncol. 2011; 29( 13)1715-1721.
7. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination
with chemotherapy versus chemotherapy alone for treatment of HER2-positive
advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.
8. Wieder HA, Brücher BL, Zimmermann F, et al. Time course of tumor metabolic
activity during chemoradiotherapy of esophageal squamous cell carcinoma and
response to treatment. J Clin Oncol. 2004; 22( 5):900-908.
9. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival,
and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol.
2006; 24( 29):4692-4698.
10. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and
to guide treatment of adenocarcinoma of the oesophagogastric junction: The
MUNICON phase II trial. Lancet Oncol. 2007; 8( 9):797-805.
11. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by
fluorine- 18 fluorodeoxyglucose positron emission tomography allows in vivo
testing of chemosensitivity in gastric cancer: Long-term results of a prospective
study. Clin Cancer Res. 2008; 14( 7):2012-2018.
12. Shah MA, Yeung H, Coit D, et al. A phase II study of preoperative chemotherapy
with irinotecan (CPT) and cisplatin (CIS) for gastric cancer (NCI 5917): FDG-PET/
CT predicts patient outcome. American Society of Clinical Oncology, Annual
Proceedings, Orlando, FL, 2007.
either salvage perioperative
chemotherapy with docetaxel/
irinotecan for two cycles,
followed by surgery and
additional chemotherapy in the
adjuvant setting, or to surgical
resection as the next step,
followed by chemoradiation.
This study is actively recruiting.
This is an important national
study that seeks to answer these
questions: Does it matter if
we identify poorly responding
patients early in the treatment
plan? And can altering therapy
affect their outcomes? The
findings of this study could
substantially improve the
outcomes in those gastric
cancer patients who have the
worst prognosis. Any interest
or support is appreciated.
For additional information,
contact Manish A. Shah, MD
or Vivian E. Strong, MD, FACS
( email@example.com). ♦
This is an important national study that seeks to
answer these questions: Does it matter if we identify
poorly responding patients early in the treatment plan?
And can altering therapy affect their outcomes?